News archive
Showing 680 results
September 2018
-
Media Release
Novartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project
-
Media Release
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis
- The PARADIGMS study was the basis for the US Food and Drug Administration (FDA) approval of Gilenya (fingolimod) in May 2018 for pediatric patients (aged 10 to 17) with relapsing multiple sclerosis… -
Media Release
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis
July 2018
-
Media Release
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
- Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer… -
Media Release
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
-
Media Release
Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices… -
Media Release
Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
-
Media Release
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
- Voluntary recall and notice of corrective action issued after discovering certain blister card packages distributed in the U.S. do not meet U.S. child-resistant packaging requirements- Certain lots… -
Media Release
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
June 2018
-
Media Release
Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
- The My Migraine Voice survey involved more than 11,000 people globally, 10% of which were from the US, and highlights urgent need for better care for benefit of patients and society- In the US,… -
Media Release
Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
-
Media Release
Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community
- STEP (Solutions to Empower Patients)™ Program helps nonprofit organizations deliver innovative solutions to patient communities - Funded programs aim to improve the experience of people living…